Search

Purpose: To evaluate the long-term efficacy of combined radiotherapy (RT) and hyperthermia (HT) in a large mono-institutional cohort of breast cancer (BC) patients affected by recurrent, newly diagnosed non-resectable or high risk resected tumor., Materials and Methods: Records of BC patients treated with RT + HT between 1995 and 2018 were retrospectively analyzed. RT doses of 50-70 Gy concurrent to a twice per week superficial HT were applied. For HT, a temperature between 41 and 42 °C was applied for approximately 1 h. Primary endpoint was local control (LC), secondary endpoints comprised toxicity, overall survival (OS), and progression-free survival (PFS)., Results: A total of 191 patients and 196 RT + HT treatments were analyzed. In 154 cases (78.6%) RT + HT was performed for patients with recurrent BC. Among these, 93 (47.4% of the entire cohort) had received RT prior to RT + HT. Median follow up was 12.7 years. LC at 2, 5, and 10 years was 76.4, 72.8, and 69.5%, respectively. OS at 2, 5, and 10 years was 73.5, 52.3, and 35.5%, respectively. PFS at 2, 5, and 10 years was 55.6, 41, and 33.6%, respectively. Predictive factors for LC were tumor stage, distant metastases, estrogen/progesterone receptor expression, resection status and number of HT fractions. At multivariate analysis tumor stage and receptor expression were significant. No acute or late toxicities higher than grade 3 were observed., Conclusion: Combined RT + HT offers long-term high LC rates with acceptable toxicity for patients with recurrent, newly diagnosed non-resectable or resected BC at high risk of relapse.

Background and Purpose: Hybrid magnetic resonance linear accelerator (MR-Linac) systems represent a novel technology for online adaptive radiotherapy. 3D secondary dose calculation (SDC) of online adapted plans is required to assure patient safety. Currently, no 3D-SDC solution is available for 1.5T MR-Linac systems. Therefore, the aim of this project was to develop and validate a method for online automatic 3D-SDC for adaptive MR-Linac treatments., Materials and Methods: An accelerator head model was designed for an 1.5T MR-Linac system, neglecting the magnetic field. The use of this model for online 3D-SDC of MR-Linac plans was validated in a three-step process: (1) comparison to measured beam data, (2) investigation of performance and limitations in a planning phantom and (3) clinical validation using n = 100 patient plans from different tumor entities, comparing the developed 3D-SDC with experimental plan QA., Results: The developed model showed median gamma passing rates compared to MR-Linac base data of 84.7%, 100% and 99.1% for crossplane, inplane and depth-dose-profiles, respectively. Comparison of 3D-SDC and full dose calculation in a planning phantom revealed that with ⩾ 5 beams gamma passing rates > 95% can be achieved for central target locations. With a median calculation time of 1:23 min, 3D-SDC of online adapted clinical MR-Linac plans demonstrated a median gamma passing rate of 98.9% compared to full dose calculation, whereas experimental plan QA reached 99.5%., Conclusion: Here, we describe the first technical 3D-SDC solution for online adaptive MR-guided radiotherapy. For clinical situations with peripheral targets and a small number of beams additional verification appears necessary. Further improvement may include 3D-SDC with consideration of the magnetic field., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2021 The Author(s).)

Background: Cure- and toxicity rates after intensity-modulated radiotherapy (IMRT) of prostate cancer are dose-and volume dependent. We prospectively studied the potential for organ at risk (OAR) sparing and compensation of tumor movement with the coverage probability (CovP) concept., Patients and Methods: Twenty-eight prostate cancer patients (median age 70) with localized disease (cT1c-2c, N0, M0) and intermediate risk features (prostate-specific antigen [PSA] < 20, Gleason score ≤ 7b) were treated in a prospective study with the CovP concept. Planning-CTs were performed on three subsequent days to capture form changes and movement of prostate and OARs. The clinical target volume (CTV) prostate and the OARs (bladder and rectum) were contoured in each CT. The union of CTV1-3 was encompassed by an isotropic margin of 7 mm to define the internal target volume (ITV). Dose prescription/escalation depended on coverage of all CTVs within the ITV. IMRT was given in 39 fractions to 78 Gy using the Monte-Carlo algorithm. Short-term androgen deprivation was recommended and given in 78.6% of patients., Results: Long-term toxicity was evaluated in 26/28 patients after a median follow-up of 7.1 years. At last follow-up, late bladder toxicity (Radiation Therapy Oncology Group, RTOG) G1 was observed in 14.3% of patients and late rectal toxicities (RTOG) of G1 (7.1%) and of G2 (3.6%) were observed. No higher graded toxicity occurred. After 7.1 years, biochemical control (biochemically no evidence of disease, bNED) was 95.5%, prostate cancer-specific survival and the distant metastasis-free survival after 7.1 years were 100% each., Conclusions: CovP-based IMRT was feasible in a clinical study. Dose escalation with the CovP concept was associated by a low rate of toxicity and a high efficacy regarding local and distant control., (© 2021 Daniel Wegener, Bernhard Berger, Zhoulika Outtagarts, Daniel Zips, Frank Paulsen, Martin Bleif, Daniela Thorwarth, Markus Alber, Oliver Dohm, Arndt-Christian Müller, published by Sciendo.)

MR-guided radiotherapy requires novel quality assurance (QA) methods for intensity-modulated radiotherapy treatment plans (TPs). Here, an optimized method for TPs for a 1.5 T MR-linac was developed and implemented clinically. A static solid phantom and an MR-compatible 2D ionization chamber array were used. The array's response with respect to the incident beam gantry angles was characterized for four different orientations of the array relative to the beam. A lookup table was created identifying the optimum orientation for each gantry angle. For the QA of clinical MR-linac TPs, beams were grouped according to their gantry angles and measured with up to four setups. The method was applied to n = 106 clinical TPs of 54 patients for different tumour entities. Reference plans and plans created in the online adaptive workflow were analysed, using a local 3%/3 mm gamma criterion for dose values larger than 30% of the maximum. Pass rates were averaged over all beam groups. The array's response strongly depends on the beam incidence angle. Optimum angles typically range from -10° to 80° around the phantom setup angle. Consequently, plan verification required up to four setups. For clinical MR-linac TPs, the overall median pass rate was 98.5% (range 88.6%-100%). Pass rates depended on the tumour entity. Median pass rates were for liver metastases stereotactic body radiotherapy 99.2%, prostate cancer 99%, pancreatic cancer 98.9%, lymph node metastases 98.7%, partial breast irradiation (PBI) 98%, head-and-neck cancer 97.7%, rectal cancer 94% and others 96.6%. 85% of plans were accepted straightaway, with pass rates above 95%. A single plan with a pass rate below 90% was subsequently verified with a modified method. Off-axis target volumes, e.g. PBI, were verified successfully using a lateral shift of the phantom. The method is suitable to verify reference and online adapted TPs for a 1.5 T MR-linac, including plans for off-axis target volumes.

Purpose: Cure- and toxicity rates of prostate IGRT can both be affected by ill-chosen planning target volume (PTV) margins. For dose-escalated prostate radiotherapy, we studied the potential for organ at risk (OAR) sparing and compensation of prostate motion with robust plan optimization using the coverage probability (CovP) concept compared to conventional PTV-based IMRT. Material and methods: We evaluated plan quality of CovP-plans for 27 intermediate risk prostate cancer patients treated in a prospective study (78 Gy/39 fractions). Clinical target volume (CTV) and OARs were contoured on three separate CTs to capture movement and deformation. To define the internal target volume (ITV), the union of CTV1-3 was encompassed by an isotropic margin of 7 mm for the planning process. CovP-dose distribution is optimized considering weight factors for IMRT constraints derived from probabilities of systematic organ displacement in the three CTs. CovP-dose volume histograms (DVHs) were compared with additionally calculated conventional PTV-based IMRT plans. PTV-based IMRT was planned on one-single CT with an isotropically expanded CTV to generate the PTV (i.e., CTV1 + 7mm) and was evaluated on the two other CTs. Results: The CovP-concept showed higher robustness in target volume coverage. Target miss was frequently observed with PTV-based IMRT, resulting in cold spots until 70 Gy with the CovP-concept. The target dose at 74 Gy was comparable, while further the dose-escalation (75-78 Gy) was improved with PTV-based IMRT. However, dose-escalation with PTV-based IMRT was associated with increased OAR-doses, especially in high-dose areas. Conclusions: Probabilistic dose-escalated IMRT was feasible in this prospective study. Comparison of the CovP-concept with PTV-based IMRT revealed superiority with regard to target-coverage and sparing of OARs. The CovP-concept implements a robust plan optimization strategy for organ deformation and motions and could, therefore, serve as a less demanding compromise on the way to adaptive IGRT avoiding daily time-consuming re-planning. SUMMARYWe evaluated the robustness of coverage probability (CovP)-based IMRT plans within a prospective study for prostate cancer radiotherapy. The treatment plans were compared with newly calculated conventional PTV-based IMRT plans. We were able to show that CovP led to a clearly more robust target coverage by avoiding hot spots at OARs compared to conventional PTV-based IMRT. In addition, negative consequences of an inflated PTV can be ameliorated by a more relaxed CovP-based dose prescription.

Introduction: External beam partial breast irradiation (PBI) provides equal oncological outcomes compared to whole breast irradiation when applied to patients with low risk tumours. Recently, linacs with an integrated magnetic resonance image-guidance system have become clinically available. Here we report the first-in-human PBI performed at the 1.5 T MR-Linac, with a focus on clinical feasibility and investigation of the air electron stream effect (ESE) and the electron return effect (ERE) in the presence of the 1.5 T magnetic field, which might influence the dose on the chin (out-of-field dose, due to the ESE), the skin and the lung/chest wall interface (in-field dose, ERE)., Methods: A 59 years old patient affected by a 15 mm unifocal grade 1 carcinoma not special type of the right breast staged pT1c pN0 cM0 was planned and treated at Unity 1.5 T MR-Linac. To investigate the ERE and the ESE, an MR-Linac treatment plan was simulated without considering the 1.5 T B field using a research version of Monaco (V. 5.19.03). In vivo dosimetry was performed using Gafchromic® EBT3 films placed on top and underneath a 1 cm bolus which was placed on the patient's chin. The plans with and without 1.5 T magnetic field were compared in terms of dose to the chin, to the skin and to the interface lung/chest wall. Finally, the dose on the chin measured with the in vivo dosimetry was compared with the dose calculated by Monaco., Results: PBI using the 1.5 T MR-Linac was successfully performed with a 7 MV photon 7-beams IMRT step-and-shoot plan. The treatment was well tolerated, the patient developed a slight acute toxicity, i.e. breast skin erythema and breast oedema CTC V.4 grade 1. The plan with 1.5 T magnetic field documented a fractional dose of 0.17 Gy in the chin area (2.6 Gy in 15 fractions), which was reduced to 0.05 Gy (0.75 in 15 fractions) by the presence of 1 cm bolus. The simulated plan without magnetic field showed a dose reduced by 2.3 Gy in the chin area. With the in vivo dosimetry a fractional dose of, respectively, 0.12 Gy and 0.034 Gy on top and underneath the bolus were measured (1.8 and 0.51 Gy in 15 fractions). The plan with 1.5 T magnetic field showed a skin D 2 of 40 Gy and a skin V 35 of 40.2%, which were reduced to, respectively, 39.7 Gy and 24.9% in the simulation without magnetic field. At the interface lung/chest there were no differences in DVH statistics., Conclusion: PBI with the 1.5 T MR-Linac was performed for the first time. ESE is accurately calculated by the treatment planning system, can be effectively reduced with a 1 cm bolus and is comparable to dose of cone beam-CT based position verification. The additional dose caused by ERE is not associated with an increased risk of acute toxicity., (Copyright © 2019 Elsevier B.V. All rights reserved.)

In this study, a Monte Carlo (MC)-based beam model for an ELEKTA linear accelerator was established. The beam model is based on the EGSnrc Monte Carlo code, whereby electron beams with nominal energies of 10, 12 and 15 MeV were considered. For collimation of the electron beam, only the integrated photon multi-leaf-collimators (MLCs) were used. No additional secondary or tertiary add-ons like applicators, cutouts or dedicated electron MLCs were included. The source parameters of the initial electron beam were derived semi-automatically from measurements of depth-dose curves and lateral profiles in a water phantom. A routine to determine the initial electron energy spectra was developed which fits a Gaussian spectrum to the most prominent features of depth-dose curves. The comparisons of calculated and measured depth-dose curves demonstrated agreement within 1%/1 mm. The source divergence angle of initial electrons was fitted to lateral dose profiles beyond the range of electrons, where the imparted dose is mainly due to bremsstrahlung produced in the scattering foils. For accurate modelling of narrow beam segments, the influence of air density on dose calculation was studied. The air density for simulations was adjusted to local values (433 m above sea level) and compared with the standard air supplied by the ICRU data set. The results indicate that the air density is an influential parameter for dose calculations. Furthermore, the default value of the BEAMnrc parameter 'skin depth' for the boundary crossing algorithm was found to be inadequate for the modelling of small electron fields. A higher value for this parameter eliminated discrepancies in too broad dose profiles and an increased dose along the central axis. The beam model was validated with measurements, whereby an agreement mostly within 3%/3 mm was found.

For plane-parallel chambers used in electron dosimetry, modern dosimetry protocols recommend a cross-calibration against a calibrated cylindrical chamber. The rationale for this is the unacceptably large (up to 3-4%) chamber-to-chamber variations of the perturbation factors (pwall)Co, which have been reported for plane-parallel chambers of a given type. In some recent publications, it was shown that this is no longer the case for modern plane-parallel chambers. The aims of the present study are to obtain reliable information about the variation of the perturbation factors for modern types of plane-parallel chambers, and-if this variation is found to be acceptably small-to determine type-specific mean values for these perturbation factors which can be used for absorbed dose measurements in electron beams using plane-parallel chambers. In an extensive multi-center study, the individual perturbation factors pCo (which are usually assumed to be equal to (pwall)Co) for a total of 35 plane-parallel chambers of the Roos type, 15 chambers of the Markus type and 12 chambers of the Advanced Markus type were determined. From a total of 188 cross-calibration measurements, variations of the pCo values for different chambers of the same type of at most 1.0%, 0.9% and 0.6% were found for the chambers of the Roos, Markus and Advanced Markus types, respectively. The mean pCo values obtained from all measurements are [Formula: see text] and [Formula: see text]; the relative experimental standard deviation of the individual pCo values is less than 0.24% for all chamber types; the relative standard uncertainty of the mean pCo values is 1.1%.

The presented virtual energy fluence (VEF) model of the patient-independent part of the medical linear accelerator heads, consists of two Gaussian-shaped photon sources and one uniform electron source. The planar photon sources are located close to the bremsstrahlung target (primary source) and to the flattening filter (secondary source), respectively. The electron contamination source is located in the plane defining the lower end of the filter. The standard deviations or widths and the relative weights of each source are free parameters. Five other parameters correct for fluence variations, i.e., the horn or central depression effect. If these parameters and the field widths in the X and Y directions are given, the corresponding energy fluence distribution can be calculated analytically and compared to measured dose distributions in air. This provides a method of fitting the free parameters using the measurements for various square and rectangular fields and a fixed number of monitor units. The next step in generating the whole set of base data is to calculate monoenergetic central axis depth dose distributions in water which are used to derive the energy spectrum by deconvolving the measured depth dose curves. This spectrum is also corrected to take the off-axis softening into account. The VEF model is implemented together with geometry modules for the patient specific part of the treatment head (jaws, multileaf collimator) into the XVMC dose calculation engine. The implementation into other Monte Carlo codes is possible based on the information in this paper. Experiments are performed to verify the model by comparing measured and calculated dose distributions and output factors in water. It is demonstrated that open photon beams of linear accelerators from two different vendors are accurately simulated using the VEF model. The commissioning procedure of the VEF model is clinically feasible because it is based on standard measurements in air and water. It is also useful for IMRT applications because a full Monte Carlo simulation of the treatment head would be too time-consuming for many small fields.

The dosimetry protocols DIN 6800-2 and AAPM TG-51, both based on the absorbed dose to water concept, are compared in their theoretical background and in their application to electron dosimetry. The agreement and disagreement in correction factors and energy parameters used in both protocols will be shown and discussed. Measurements with three different types of ionization chambers were performed and evaluated according to both protocols. As a result the perturbation correction factor P(60Co)wall for the Roos chamber was determined to 1.024 +/- 0.5%.